Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/16011
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGrabez M.-
dc.contributor.authorŠkrbić R.-
dc.contributor.authorStojiljković M.-
dc.contributor.authorVucic, Vesna-
dc.contributor.authorGrujic V.-
dc.contributor.authorJakovljevic, Vladimir-
dc.contributor.authorDjuric, Dragan M.-
dc.contributor.authorSurucic R.-
dc.contributor.authorŜavikin K.-
dc.contributor.authorBigovic D.-
dc.contributor.authorVasiljević N.-
dc.date.accessioned2023-02-08T16:17:27Z-
dc.date.available2023-02-08T16:17:27Z-
dc.date.issued2022-
dc.identifier.issn1530-6550-
dc.identifier.urihttps://scidar.kg.ac.rs/handle/123456789/16011-
dc.description.abstractBackground: Type 2 diabetes mellitus (T2DM) is commonly associated with hyperglycemia, dyslipidemia, oxidative stress and inflammation which are well known cardiovascular risk factors. Pomegranate peel polyphenols have a proven hypolipemic, antioxidant and anti-inflammatory activity. However, there is a lack of clinical studies that would confirm its antioxidant and anti-inflammatory effects in diabetic patients. The potential of pomegranate peel extract (PoPEx) to counteract inflammation and oxidative stress in T2DM patients was investigated. For this purpose, a randomized, double-blind placebo-controlled study involving adult T2DM patients treated with PoPEx or placebo for eight-weeks was conducted. Methods: Patients were randomly divided into two groups: The first group (n = 30) received capsules containing PoPEx 250 mg twice daily, while the placebo group (n = 30) received placebo capsules twice daily. Plasma concentration of inflammatory factors (interleukin 6 (IL-6), tumor necrosis factor α (TNF-α) and high sensitivity C reactive protein (hsCRP)), oxidative stress biomarkers (thiobarbituric acid reactive substances (TBARS), nitrites (NO2 -), superoxide anion radical (O2 -), hydrogen peroxide (H2O2), total antioxidant capacity (TAC)), homocysteine and lipid profile were analyzed. Results: The PoPEx treatment showed a significant reduction of inflammatory factors (IL-6, TNF-α, hsCRP), oxidative stress biomarkers (TBARS, NO2 -, O2 -) and homocysteine, while the TAC was increased. Moreover, a significant improvement in lipid profile was observed in the PoPEx group. Additional analysis showed a significant inverse correlation between the decrements of all measured inflammatory markers and TAC in the PoPEx group. Conclusions: The study demonstrated that eight-week-long PoPEx administration had favorable effects on inflammatory status and oxidative stress biomarkers in diabetic patients.-
dc.rightsinfo:eu-repo/semantics/restrictedAccess-
dc.sourceReviews in Cardiovascular Medicine-
dc.titleA prospective, randomized, double-blind, placebo-controlled trial of polyphenols on the outcomes of inflammatory factors and oxidative stress in patients with type 2 diabetes mellitus-
dc.typearticle-
dc.identifier.doi10.31083/j.rcm2302057-
dc.identifier.scopus2-s2.0-85125589643-
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)

383

Downloads(s)

5

Files in This Item:
File Description SizeFormat 
PaperMissing.pdf
  Restricted Access
29.86 kBAdobe PDFThumbnail
View/Open


Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.